Developer docs
API playgroundTry for free, no card

Search company profiles

LatchBio

Full company profile

uuid0000662

Namestring
LatchBio
Legal namestring
LatchBio, Inc.
Websiteurl
latch.bio
Company typeenum
Private
Founded yearint
2021
Descriptiontext

LatchBio is a San Francisco-based biotechnology software company founded in 2021 that provides a cloud-based, code-free platform for bioinformatics data analysis. Its core product combines five modules — Workflows (Nextflow/Snakemake/Python SDK orchestration), Pods (scalable compute), Plots (interactive visualizations), Registry (experimental metadata), and centralized File Storage — with a library of verified pre-built pipelines for assays such as Bulk RNA-seq, scRNA-seq, AlphaFold, CRISPResso2, CAS-OFFinder, CRISPOR, and MAGeCK. An AI Agent powered by Claude 4.5 Opus adds natural-language cell-type identification across multimodal data formats.

The platform serves two primary customer segments: (1) biopharma and R&D labs (300+ including Amgen, GSK, Takeda, Broad Institute, AstraZeneca, Arc Institute, Elsie Biotechnologies) requiring IND-ready, SOC 2 Type II and 21 CFR Part 11 compliant analysis for drug discovery and regulated workflows, and (2) solution providers — NGS kit and instrument manufacturers such as Illumina, SeqWell, Fluent BioSciences, HaspBio, and Curio — who deploy white-labeled customer portals on LatchBio's infrastructure to attach downstream analysis to their reagents and accelerate kit repurchases. The company claims 72% cost savings versus AWS, GCP, and Azure and an 80% reduction in per-run RNA-seq cost ($2,000 to $150), validated by named customer testimonials.

LatchBio monetizes through usage-based pricing on cloud compute and storage (no seat or licensing fees) supplemented by professional services for integration, onboarding, and training, with an enterprise direct-sales motion layered on top of self-serve PLG acquisition. Distribution is global via a web console (console.latch.bio), white-labeled OEM portals, and Python API endpoints. Capital structure is private, venture-backed, with a $28 million Series A led by Coatue and Lux Capital in June 2022 and no subsequently announced funding round in the source data.

Short descriptiontext

LatchBio is a San Francisco-based biotech software company that provides a cloud-based, code-free bioinformatics platform for analyzing biological data, serving 300+ biopharma and R&D labs and 40+ kit/instrument solution providers with usage-based pricing and AI-assisted workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioinformatics software, cloud data platform, genomics analysis, computational biology tools, biological data processing
Industry2 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Software Publishers5132
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Cloud Bioinformatics Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Cloud Platform Access
TypeUsage Based
Description

Usage-based pricing model for accessing the LatchBio cloud platform for biological data analysis. Users pay only for compute and storage resources consumed.

latch.bio:443
2Professional Services
TypeProfessional Services
Description

Integration, onboarding, training, and other professional services for enterprise customers.

latch.bio:443
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Usage-based pricing with no seat/licensing costs
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Simple, usage-based pricing model where customers only pay for what they use. Licensing and seat costs are not charged. Customer quote indicates $150 per RNA-seq analysis compared to $2,000 traditional cost.

latch.bio:443
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

LatchBio provides a modular, code-free cloud-based bioinformatics data analysis platform that enables biological researchers to process and interpret data from over 40 NGS kits and instruments without coding or cloud infrastructure expertise. The platform combines serverless workflow orchestration, scalable compute pods, interactive visualizations, and an AI Agent for biology to deliver reproducible, IND-ready analyses for biopharma R&D teams, and offers white-labeled analysis portals for NGS solution providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 80% cost reduction for RNA-seq data analysis ($2,000 to $150 per run)
+2 more records
Product overview1 text field

LatchBio is a modular cloud-based data platform for biological research analysis, featuring a platform-plus-modules architecture. The core platform consists of Plots (interactive visualizations), Pods (scalable compute instances), Workflows (orchestration with Nextflow/Snakemake/Python SDK), Registry (metadata management), and File Storage (centralized data management). The platform offers pre-built Verified Workflows for common bioinformatics assays including Bulk RNA-Seq, AlphaFold, CRISPResso2, CAS-OFFinder, CRISPOR, and MAGeCK, along with specialized solutions for Spatial Transcriptomics, Gene Editing, qPCR, and ATAC-Seq. An AI Agent powered by Claude 4.5 Opus enables natural language interaction with biological data. The platform serves 40+ solution providers and 300+ biopharmas and R&D labs, supporting 40+ kits and instruments with usage-based pricing offering over 72% cost savings versus AWS, GCP, and Azure.

Product and service5 records
1LatchBio Cloud Platform
CategoryCloud Bioinformatics Platform
Description

Cloud-based bioinformatics platform enabling bench scientists, computational biologists, and R&D teams to analyze data from 40+ supported kits and instruments without coding or cloud infrastructure expertise. Used by 4,000+ scientists and 300+ biopharmas and R&D labs.

2Solution Providers White-Label Portal
CategoryWhite-Label Bioinformatics Solution
Description

Customizable, white-labeled analysis portal offered to NGS kit providers, instrument manufacturers, and assay developers so they can deliver branded data analysis to their customers. Deployable in under four weeks with no extra cost per customer.

3AI Agent for Biology Data Analysis
CategoryAI Bioinformatics Feature
Description

AI-powered agent embedded in the LatchBio platform that identifies cell types in single-cell and spatial biology datasets and processes multimodal biological data files, enabling natural-language interaction with biological data.

4Latch Developer SDKs (Python, Nextflow, Snakemake)
CategoryDeveloper Tools / Bioinformatics SDKs
Description

Developer toolchain comprising the open-source Python SDK, the Nextflow SDK, and the Snakemake SDK, allowing bioinformaticians to define serverless workflows in plain Python, Nextflow, or Snakemake and deploy corresponding no-code interfaces on LatchBio's managed cloud infrastructure.

5Verified Bioinformatics Workflows
CategoryPre-built Bioinformatics Pipelines
Description

Pre-built, optimized workflows for common assays including Bulk RNA-seq (alignment and differential expression), scRNA-seq, AlphaFold protein structure prediction, ColabFold, CRISPResso2, CAS-OFFinder, CRISPOR, and the MAGeCK CRISPR screen suite, runnable on the LatchBio cloud platform.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

LatchBio migrated Scantox's DuplexSeq error-corrected sequencing technology to a scalable cloud-based bioinformatics platform. Migration restores customer access to mutagenesis assays with reagent kits available immediately and expanded commercial availability expected Q3 2026.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-12
Description

Supported the technical migration of DuplexSeq bioinformatics to LatchBio's cloud platform. Clint Valentine, original pipeline architect, led the migration confirming equivalent outputs to the original TwinStrand pipeline.

3Takara Bio
Strategic tierCoreTypeGTM or Marketing Partner
Description

Joint webinar partnership on spatial analysis of Seeker and Trekker Datasets. Takara Bio's instruments supported on the LatchBio platform.

latch.bio:443
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cloud-based genomics and biomedical data analysis platform serving pharma, clinical labs, and consortia. Directly comparable as a managed bioinformatics workflow platform with enterprise-grade compliance, similar to LatchBio's positioning.

TypeDirect peer
Description

Biomedical informatics platform offering cloud-based workflows for genomics, multi-omics, and clinical analysis. Directly overlaps LatchBio in bioinformatics-as-a-service for pharma and clinical research customers.

TypeBroad incumbent
Description

Broader life science R&D cloud platform with expanding bioinformatics and omics capabilities. Larger, well-funded incumbent that competes for the same biopharma R&D budget with a wider product suite that now encroaches on LatchBio's sequencing analysis territory.

4AWS HealthOmics
TypeBroad incumbent
Description

Hyperscaler bioinformatics service offering managed genomics and multi-omics pipelines on AWS infrastructure. Competes on the same cloud-bioinformatics workload with deep cloud-native integration that LatchBio must position against on cost and ease-of-use.

TypeBroad incumbent
Description

Google's cloud-based platform for processing genomics and biomedical data at scale. Overlaps with LatchBio's cloud workflow orchestration and benefits from underlying GCP integration similar to how LatchBio competes on cost versus GCP.

TypeBroad incumbent
Description

Illumina's cloud informatics suite for sequencing data management and analysis. A sequencing-instrument vendor's embedded platform, comparable to LatchBio's white-label model serving Illumina and other kit providers.

TypeDirect peer
Description

Genomics data analysis and interpretation platform serving clinical and research labs. Comparable as a specialized bioinformatics analysis platform with clinical-grade capabilities and a similar target customer base.

TypeDirect peer
Description

Genomics and clinical data management platform used by pharma, biobanks, and research networks. Directly comparable in offering cloud-based bioinformatics data analysis to regulated life science customers.

TypeEmerging player
Description

Sequencing instrument vendor with growing cloud informatics capabilities. Represents the emerging category of instrument makers bundling analysis software, which competes with LatchBio's solution-provider model.

10nf-core
TypeOthers
Description

Community-curated set of best-practice Nextflow bioinformatics pipelines. The dominant open-source alternative that LatchBio packages and operationalizes, representing the free substitute that caps LatchBio's pricing power.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LatchBio

Cloud Bioinformatics Softwarelatch.bio

LatchBio is a San Francisco-based biotech software company that provides a cloud-based, code-free bioinformatics platform for analyzing biological data, serving 300+ biopharma and R&D labs and 40+ kit/instrument solution providers with usage-based pricing and AI-assisted workflows.

What LatchBio does

LatchBio is a San Francisco-based biotechnology software company founded in 2021 that provides a cloud-based, code-free platform for bioinformatics data analysis. Its core product combines five modules — Workflows (Nextflow/Snakemake/Python SDK orchestration), Pods (scalable compute), Plots (interactive visualizations), Registry (experimental metadata), and centralized File Storage — with a library of verified pre-built pipelines for assays such as Bulk RNA-seq, scRNA-seq, AlphaFold, CRISPResso2, CAS-OFFinder, CRISPOR, and MAGeCK. An AI Agent powered by Claude 4.5 Opus adds natural-language cell-type identification across multimodal data formats.

The platform serves two primary customer segments: (1) biopharma and R&D labs (300+ including Amgen, GSK, Takeda, Broad Institute, AstraZeneca, Arc Institute, Elsie Biotechnologies) requiring IND-ready, SOC 2 Type II and 21 CFR Part 11 compliant analysis for drug discovery and regulated workflows, and (2) solution providers — NGS kit and instrument manufacturers such as Illumina, SeqWell, Fluent BioSciences, HaspBio, and Curio — who deploy white-labeled customer portals on LatchBio's infrastructure to attach downstream analysis to their reagents and accelerate kit repurchases. The company claims 72% cost savings versus AWS, GCP, and Azure and an 80% reduction in per-run RNA-seq cost ($2,000 to $150), validated by named customer testimonials.

LatchBio monetizes through usage-based pricing on cloud compute and storage (no seat or licensing fees) supplemented by professional services for integration, onboarding, and training, with an enterprise direct-sales motion layered on top of self-serve PLG acquisition. Distribution is global via a web console (console.latch.bio), white-labeled OEM portals, and Python API endpoints. Capital structure is private, venture-backed, with a $28 million Series A led by Coatue and Lux Capital in June 2022 and no subsequently announced funding round in the source data.

LatchBio firmographics

Firmographics
Name
LatchBio
Legal name
LatchBio, Inc.
Website
https://latch.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
LatchBio is a San Francisco-based biotech software company that provides a cloud-based, code-free bioinformatics platform for analyzing biological data, serving 300+ biopharma and R&D labs and 40+ kit/instrument solution providers with usage-based pricing and AI-assisted workflows.
Ownership category
akta.pro rank

LatchBio industry classification

Industry
Product category
Cloud Bioinformatics Software
NAICS
Software Publishers (5132), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Bioinformatics software
  • Cloud data platform
  • Genomics analysis
  • Computational biology tools
  • Biological data processing

Where LatchBio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

LatchBio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations

Revenue model

  1. Cloud Platform Access: Usage-based pricing model for accessing the LatchBio cloud platform for biological data analysis. Users pay only for compute and storage resources consumed.
  2. Professional Services: Integration, onboarding, training, and other professional services for enterprise customers.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goUsage-based pricing with no seat/licensing costs

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

LatchBio product offering

Product offering

Core offering

LatchBio provides a modular, code-free cloud-based bioinformatics data analysis platform that enables biological researchers to process and interpret data from over 40 NGS kits and instruments without coding or cloud infrastructure expertise. The platform combines serverless workflow orchestration, scalable compute pods, interactive visualizations, and an AI Agent for biology to deliver reproducible, IND-ready analyses for biopharma R&D teams, and offers white-labeled analysis portals for NGS solution providers.

Product overview

LatchBio is a modular cloud-based data platform for biological research analysis, featuring a platform-plus-modules architecture. The core platform consists of Plots (interactive visualizations), Pods (scalable compute instances), Workflows (orchestration with Nextflow/Snakemake/Python SDK), Registry (metadata management), and File Storage (centralized data management). The platform offers pre-built Verified Workflows for common bioinformatics assays including Bulk RNA-Seq, AlphaFold, CRISPResso2, CAS-OFFinder, CRISPOR, and MAGeCK, along with specialized solutions for Spatial Transcriptomics, Gene Editing, qPCR, and ATAC-Seq. An AI Agent powered by Claude 4.5 Opus enables natural language interaction with biological data. The platform serves 40+ solution providers and 300+ biopharmas and R&D labs, supporting 40+ kits and instruments with usage-based pricing offering over 72% cost savings versus AWS, GCP, and Azure.

Differentiator

Problem solved

Functional benefit

Products and services

  • LatchBio Cloud Platform Cloud-based bioinformatics platform enabling bench scientists, computational biologists, and R&D teams to analyze data from 40+ supported kits and instruments without coding or cloud infrastructure expertise. Used by 4,000+ scientists and 300+ biopharmas and R&D labs.
  • Solution Providers White-Label Portal Customizable, white-labeled analysis portal offered to NGS kit providers, instrument manufacturers, and assay developers so they can deliver branded data analysis to their customers. Deployable in under four weeks with no extra cost per customer.
  • AI Agent for Biology Data Analysis AI-powered agent embedded in the LatchBio platform that identifies cell types in single-cell and spatial biology datasets and processes multimodal biological data files, enabling natural-language interaction with biological data.
  • Latch Developer SDKs (Python, Nextflow, Snakemake) Developer toolchain comprising the open-source Python SDK, the Nextflow SDK, and the Snakemake SDK, allowing bioinformaticians to define serverless workflows in plain Python, Nextflow, or Snakemake and deploy corresponding no-code interfaces on LatchBio's managed cloud infrastructure.
  • Verified Bioinformatics Workflows Pre-built, optimized workflows for common assays including Bulk RNA-seq (alignment and differential expression), scRNA-seq, AlphaFold protein structure prediction, ColabFold, CRISPResso2, CAS-OFFinder, CRISPOR, and the MAGeCK CRISPR screen suite, runnable on the LatchBio cloud platform.

Quantifiable outcome

  • 80% cost reduction for RNA-seq data analysis ($2,000 to $150 per run)
  • +2 more outcomes

Companies that use LatchBio

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

LatchBio technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature11 records

LatchBio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Scantox GroupcoreStrategic or Co-development Partner · 12 May 2026LatchBio migrated Scantox's DuplexSeq error-corrected sequencing technology to a scalable cloud-based bioinformatics platform. Migration restores customer access to mutagenesis assays with reagent kits available immediately and expanded commercial availability expected Q3 2026.
  • Fulcrum GenomicscoreTechnology or Integration · 12 May 2026Supported the technical migration of DuplexSeq bioinformatics to LatchBio's cloud platform. Clint Valentine, original pipeline architect, led the migration confirming equivalent outputs to the original TwinStrand pipeline.
  • Takara BiocoreGTM or Marketing PartnerJoint webinar partnership on spatial analysis of Seeker and Trekker Datasets. Takara Bio's instruments supported on the LatchBio platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

LatchBio competitors and assessment

Company assessment

Direct peers

  • DNAnexus: Cloud-based genomics and biomedical data analysis platform serving pharma, clinical labs, and consortia. Directly comparable as a managed bioinformatics workflow platform with enterprise-grade compliance, similar to LatchBio's positioning.
  • Velsera (formerly Seven Bridges Genomics): Biomedical informatics platform offering cloud-based workflows for genomics, multi-omics, and clinical analysis. Directly overlaps LatchBio in bioinformatics-as-a-service for pharma and clinical research customers.
  • Geneyx: Genomics data analysis and interpretation platform serving clinical and research labs. Comparable as a specialized bioinformatics analysis platform with clinical-grade capabilities and a similar target customer base.
  • BC Platforms: Genomics and clinical data management platform used by pharma, biobanks, and research networks. Directly comparable in offering cloud-based bioinformatics data analysis to regulated life science customers.

Broad incumbents

  • Benchling: Broader life science R&D cloud platform with expanding bioinformatics and omics capabilities. Larger, well-funded incumbent that competes for the same biopharma R&D budget with a wider product suite that now encroaches on LatchBio's sequencing analysis territory.
  • AWS HealthOmics: Hyperscaler bioinformatics service offering managed genomics and multi-omics pipelines on AWS infrastructure. Competes on the same cloud-bioinformatics workload with deep cloud-native integration that LatchBio must position against on cost and ease-of-use.
  • Google Cloud Life Sciences: Google's cloud-based platform for processing genomics and biomedical data at scale. Overlaps with LatchBio's cloud workflow orchestration and benefits from underlying GCP integration similar to how LatchBio competes on cost versus GCP.
  • Illumina Connected Analytics: Illumina's cloud informatics suite for sequencing data management and analysis. A sequencing-instrument vendor's embedded platform, comparable to LatchBio's white-label model serving Illumina and other kit providers.

Emerging players

  • Element Biosciences: Sequencing instrument vendor with growing cloud informatics capabilities. Represents the emerging category of instrument makers bundling analysis software, which competes with LatchBio's solution-provider model.

Others

  • nf-core: Community-curated set of best-practice Nextflow bioinformatics pipelines. The dominant open-source alternative that LatchBio packages and operationalizes, representing the free substitute that caps LatchBio's pricing power.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LatchBio social profiles

Digital presence

LatchBio compliance and trust

Trust signal

Compliance2 records

LatchBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LatchBio leadership team

Management profile

Number of profiles

Profiles4 records

LatchBio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LatchBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LatchBio

What does LatchBio do?

LatchBio provides a modular, code-free cloud-based bioinformatics data analysis platform that enables biological researchers to process and interpret data from over 40 NGS kits and instruments without coding or cloud infrastructure expertise. The platform combines serverless workflow orchestration, scalable compute pods, interactive visualizations, and an AI Agent for biology to deliver reproducible, IND-ready analyses for biopharma R&D teams, and offers white-labeled analysis portals for NGS solution providers.

Is LatchBio a public or private company?

LatchBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was LatchBio founded?

LatchBio was founded in 2021. It employs 51 to 100 people.

Where is LatchBio based?

LatchBio is headquartered in San Francisco, United States, in the North America region.

How does LatchBio make money?

Two revenue lines are on record. Cloud Platform Access are the primary driver. The others are professional Services.

Who are LatchBio's main competitors?

Direct peers on record are DNAnexus, Velsera (formerly Seven Bridges Genomics), Geneyx and BC Platforms. Broad incumbents are Benchling, AWS HealthOmics, Google Cloud Life Sciences and Illumina Connected Analytics. Element Biosciences is listed as an emerging player. nf-core is listed as an others.

Does LatchBio have an API?

Yes. The Latch SDK provides programmatic API endpoints for running workflows. Developers can define computational workflows in Python, package them into Docker images, and run them on LatchBio's managed cloud infrastructure. The SDK offers programmatic execution capabilities including programmatic API endpoints for running workflows, single line definition of arbitrary resource requirements (CPU, GPU) for serverless execution, and programmatic batch execution via CSV parameter import. The Python SDK also supports conditional sections (if-elif-else logic), task parallelization via map_task, caching and version control. Developer documentation is at docs.latch.bio.

What industry is LatchBio in?

LatchBio's product category is Cloud Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Blockchain NewsGrok 4.6 Leads Biosecurity Testing on LatchBio BenchmarksGrok 4.6 led LatchBio's BioSecBench-Refusal benchmark, scoring above 50% on both refusal and routine tasks. It refused 59.2% of adversarial requests and completed 64.8% of routine work, averaging 62.1%. The model also performed competitively in surveillance tasks, with xAI planning further safeguard refinements.RuntimewireGrok 4.6 kept its name and changed its biosecurity behavior, LatchBio saysLatchBio's September 1st analysis found the Grok 4.6 checkpoint served by SpaceXAI refused 59.2% of red-team attempts and completed 64.8% of routine tasks, scoring 62.1% on BioSecBench-Refusal. The company says this is a significant improvement over earlier Grok 4.6 versions, though it does not establish performance in live outbreak investigations.PR NewswireScantox Upgrades DuplexSeq™ Bioinformatics with Cloud-Based Mutagenesis AppScantox Group announced the launch of the Scantox DuplexSeq Mutagenesis App on a cloud-based bioinformatics platform, completing a technology transition for its error-corrected sequencing service. Clint Valentine from Fulcrum Genomics, who originally architectured the pipeline, led the migration to LatchBio, which was selected following an evaluation of available platforms. DuplexSeq reagent kits are available now, with expanded commercial availability expected in Q3 2026.MediumWhy your investment in self-service bioinformatics software was a mistake and where to invest next in TechBioThe article argues that generic commercial self-service bioinformatics software is a flawed investment due to the non-standard nature of data preprocessing and significant customer heterogeneity. It cites companies such as Lifebit, Seven Bridges, and LatchBio as examples where capital failed to create universal tools, leading many to pivot toward consultancy models or narrow their scope.YahooLatchBio Simplifies Access to GPU-Powered Multi-Omics Tools With NVIDIALatchBio announced nineteen AI protein engineering tools, 70% faster multi-omics pipelines, and one-click access to NVIDIA GPUs. The tools include AlphaFold2 and RF-Diffusion, with early adopters screening tens of thousands of proteins. The company plans to expand accelerated infrastructure for single-cell workflows and AI applications.Business Wire BlogLatchBio Simplifies Access to GPU-Powered Multi-Omics Tools With NVIDIALatchBio announced nineteen AI protein engineering tools, 70% faster multi-omics pipelines, and one-click access to NVIDIA GPUs. The company rewrote its scATAC peak-calling algorithm to cut peak-calling time 14x, and plans to continue reducing pipeline costs. Pods, a cloud portal for GPU notebooks, is also launched.The San Francisco StandardThis San Francisco startup is mandating a six-day workweekSan Francisco startup LatchBio is mandating a six-day workweek for its employees, as shown in two job postings. The company, which makes biotech data analysis software, has about 22 employees and has raised around $33 million. CEO Alfredo Andere confirmed the move was a teamwide decision but did not disclose reasons or expected results.RadioinkBiotech Podcast ‘First In Human’ Getting Its Second SeasonClinical trial manager Vial is launching the second season of its biotech podcast, 'First in Human,' with a premiere date of September 5. The new season will feature interviews with industry leaders such as executives from ONL Therapeutics, ProteinQure, and LatchBio to discuss breakthroughs and challenges in the sector.ForbesMeet The Three Berkeley Dropouts Empowering Biotechs With Low-Code Cloud-Based BiocomputingLatchBio, founded by three Berkeley dropouts, provides low-code biocomputing infrastructure for synthetic biology data analysis. The company raised $5 million in seed funding and $28 million in Series A, and has over 30 paying customers running 10,000 workflows monthly. It aims to accelerate drug discovery across the pipeline.